Lates News

According to AI Express of Every Economics, Pacific Securities released a research report on April 30th, giving Common Pharmaceuticals (300966.SZ) a buy rating. The main reasons for the rating include: 1) Steady growth in Q1 revenue, with expenses impacting profit performance during the period; 2) Large-scale capacity investment is expected to help drive rapid revenue growth; 3) Actively carrying out share buybacks to demonstrate long-term development confidence. (Daily Economic News)